{"id":"anti-parkinson-medication","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Dizziness"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Fatigue"},{"rate":"5-10%","effect":"Dyskinesia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It does this by inhibiting the enzyme responsible for breaking down dopamine, allowing more dopamine to be available for the brain's use. This leads to improved motor function and reduced symptoms of Parkinson's disease.","oneSentence":"This drug works by increasing dopamine levels in the brain to alleviate Parkinson's symptoms.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T04:10:12.316Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Parkinson's disease"},{"name":"Flu-like syndrome"}]},"trialDetails":[{"nctId":"NCT05043103","phase":"","title":"Long-Term Observational Study on Effectiveness and Safety of Lecigon in Patients With Advanced Parkinson's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Britannia Pharmaceuticals Ltd.","startDate":"2021-07-06","conditions":"Advanced Parkinson Disease","enrollment":312},{"nctId":"NCT05962957","phase":"PHASE2","title":"Role of Pentoxifylline and Celecoxib in Parkinsonism","status":"COMPLETED","sponsor":"Mostafa Bahaa","startDate":"2023-08-07","conditions":"Parkinson Disease","enrollment":80},{"nctId":"NCT02994719","phase":"","title":"Gait Analysis in Neurological Disease","status":"RECRUITING","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2016-03-01","conditions":"Parkinson's Disease, Parkinsonian Disorders, Atypical Parkinson Disease","enrollment":120},{"nctId":"NCT06841718","phase":"","title":"Investigating the Neural Signature of Freezing of Gait in Parkinson's Disease","status":"ENROLLING_BY_INVITATION","sponsor":"KU Leuven","startDate":"2024-11-04","conditions":"Parkinson Disease, Freezing of Gait, Basal Ganglia Diseases","enrollment":28},{"nctId":"NCT06665113","phase":"NA","title":"Neuroprotective Effects of Long-term TaVNS in Early Parkinson's Disease Patients","status":"RECRUITING","sponsor":"Kezhong Zhang","startDate":"2024-12-23","conditions":"Parkinson Disease, Idiopathic","enrollment":12},{"nctId":"NCT06566313","phase":"NA","title":"An Open-label Study on the Clinical Efficacy of tDCS Intervention in PD","status":"COMPLETED","sponsor":"Anhui Medical University","startDate":"2021-01-01","conditions":"Transcranial Direct Current Stimulation, Parkinson Disease, Primary Left Motor Cortex","enrollment":17},{"nctId":"NCT06365190","phase":"NA","title":"Effects of a Periodic Repetitive Transcranial Magenetic Stimulation in Parkinson Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Anhui Medical University","startDate":"2020-04-06","conditions":"Transcranial Magnetic Stimulation, Parkinson's Disease","enrollment":47},{"nctId":"NCT05997043","phase":"EARLY_PHASE1","title":"Safety and Efficacy of Botulinum Toxin A for Treatment of Overactive Bladder in Parkinson's Disease","status":"RECRUITING","sponsor":"Zhujiang Hospital","startDate":"2023-08-26","conditions":"Parkinson's Disease, Overactive Bladder, Onabotulinumtoxin A","enrollment":60},{"nctId":"NCT01770145","phase":"PHASE4","title":"Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT)","status":"COMPLETED","sponsor":"MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals","startDate":"2012-12","conditions":"Parkinson's Disease, Motor Symptoms, Akinesia","enrollment":127},{"nctId":"NCT03181282","phase":"NA","title":"Physical Therapy and Deep Brain Stimulation in Parkinson Disease","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2017-08-03","conditions":"Parkinson Disease","enrollment":31},{"nctId":"NCT01683253","phase":"PHASE4","title":"Remission of ICD by Switching Dopamine Agonist to Levodopa/Carbidopa","status":"COMPLETED","sponsor":"Sandoz","startDate":"2012-11","conditions":"Impulse Control Disorder","enrollment":150},{"nctId":"NCT04730245","phase":"PHASE1","title":"Microbiota Modification for the Treatment of Motor Complication of Parkinson´s Disease","status":"COMPLETED","sponsor":"Torre Médica Santé","startDate":"2018-06-01","conditions":"Parkinson's Disease Aggravated","enrollment":14},{"nctId":"NCT03918616","phase":"","title":"P2X7 Receptor, Inflammation and Neurodegenerative Diseases","status":"COMPLETED","sponsor":"University of Pisa","startDate":"2017-02-20","conditions":"Neuro-Degenerative Disease","enrollment":50},{"nctId":"NCT00397696","phase":"PHASE2","title":"Evaluation of 5-[123I]-A-85380 and SPECT Imaging in Individuals With Parkinsons Disease","status":"COMPLETED","sponsor":"Institute for Neurodegenerative Disorders","startDate":"2006-11","conditions":"Parkinson Disease","enrollment":9},{"nctId":"NCT00617019","phase":"","title":"Impulse Control Disorders in Parkinson's Patients Treated With Pramipexole and Other Agents (DOMINION Study)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2006-09","conditions":"Parkinson Disease","enrollment":3234},{"nctId":"NCT00443768","phase":"","title":"Medication Review in Patients on Anti-parkinson Therapy","status":"COMPLETED","sponsor":"South Glasgow University Hospitals NHS Trust","startDate":"2006-10","conditions":"Parkinson's Disease","enrollment":120},{"nctId":"NCT01190553","phase":"NA","title":"Pilot Study of Maintenance Therapy With Intravenous AMANTADINE","status":"UNKNOWN","sponsor":"Rabin Medical Center","startDate":"2010-11","conditions":"Parkinson Disease","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":57,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Carbidopa/levodopa","pramipexole","ropinirole","amantadine","tolcapone"],"phase":"phase_2","status":"active","brandName":"Anti-Parkinson medication","genericName":"Anti-Parkinson medication","companyName":"Beth Israel Deaconess Medical Center","companyId":"beth-israel-deaconess-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This drug works by increasing dopamine levels in the brain to alleviate Parkinson's symptoms. Used for Parkinson's disease, Flu-like syndrome.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}